Education and Professional Experience

• 1977 - 1980 Study of Medicine at Eberhard Karls University of Tuebingen.
• 1980 - 1981 DAAD Foundation Fellow, Owen University of Manchester.
• 1982 Guy’s Hospital London.
• 1984 Examination for a medical certificate (Tuebingen).
• 1984 Admission to medical practice.
• 1986 PhD thesis defense, Toxicology Institute Tuebingen (summa cum laude).
• 1986 Scientific Internship at the Max Planck Institute, Martinsried.
• 1984 - 1993 Assistant Physician, Department of Internal Medicine II at the University Hospital Tuebingen.
• 1991 Certified as a General Practitioner.
• 1992 Research internship at the Fred Hutchinson Cancer Research Center (FHCRC), Seattle.
• 1993 Senior Physician at the Department of Hematology, Oncology, Rheumatology and Immunology at the University Hospital Tuebingen.
• 1996 Additional qualification in Hematology and Oncology.
• 1999 Appointed as an Extraordinary Professor, University of Tuebingen.
• 2000 Visiting Professor, City of Hope Hospital, Duarte, USA.
• 2001 Head of the Department, University of Tuebingen.
• 2003 Visiting Professor, City of Hope Hospital, Duarte, USA.
• 20004 Head of the Department of Internal Medicine, Julius Maximilian University of Würzburg.
• 2008 Invitation to the position of the Head of the Department of Internal Medicine III at the Johannes Gutenberg University Mainz (rejection).
• 2011 - 2015 Deputy Dean of the Faculty of Medicine, Julius Maximilian University of Würzburg.
• Since 2015 Vice President of the Julius Maximilian University of Würzburg.

Awards

• 2003 Van Bekkum Award.
• 2011 Honorary Fellow of the Royal College of Pathologists (London).
• 2012 Nobel Lecture, Nobel Committee of the Karolinska Institute.
• Since 2014 Member of the Academy of Science and Literature, Mainz.

Positions in Scientific Societies and Institutions

• Since 1994 Leadership of the German Multiple Myeloma Research Group (DSMM).
• Board Member of the European Network on Multiple Myeloma.
• Since 2004 Head of the Working Group on Maintenance Therapy in the European Network of Competent Healthcare Institutions (EuroNet Leukemia).
• Since 2011 Member of the Management of the Research Group on Indolent Lymphomas (StiL).
• Since 2012 Board Member of the German Network of Healthcare Facilities for Malignant Lymphomas.
• 2013 - 2016 Member of the European Commission Consortium of the Research Project "T-Control".
• Since 2013 Member of the Scientific Council of the Wilhelm Sander Foundation.
• Since 2013 Co-Speaker of the Research Network of the Joint Research Center / Transregio 124 (Pathogenic fungi and human carrier organism) of the German Research Foundation.
• Since 2015 Member of the Scientific Council of the Medical Faculty of the Friedrich Schiller University Jena.
• Since 2018 Co-Speaker of the Research Network of the Joint Research Center / Transregio 221 of the German Research Foundation.

Publications:
1. Patriarca F, Bruno B, Einsele H, Spina F, Giaccone L, Montefusco V, Isola M, Nozzoli C, Nozza A, Morabito F, Corradini P, Fanin R.
Long-Term Follow-Up of a „Donor“ Versus „No Donor“ Comparison in Multiple Myeloma Patients at First Relapse after Failing
Autologous Transplantation. Biol Blood Marrow Transplant. 2017 Oct 12.
2. Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C,
Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA,
Salwender H, Hebart H, Straka C, Knop S.Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in
multiple myeloma: DSMM XI trial. Br J Haematol. 2017 Sep 29.
3. Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU,
Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J Allogeneic
Hematopoietic Cell Transplantation in Intermediate Risk Acute Myeloid Leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA
Mutations. Study Alliance Leukemia (SAL). Ann Oncol. 2017 Sep 1.
4. Richardson P, Roy A, Acharyya S, Panneerselvam A, Mendelson E, Günther A, Lonial S, Einsele H. Treatment-free interval as a metric
of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor
panobinostat, a next-generation novel agent. Expert Rev Hematol. 2017 Oct; 10.
5. Tsamadou C, Fürst D, Vucinic V, Bunjes D, Neuchel C, Mytilineos D, Gramatzki M, Arnold R, Wagner EM, Einsele H, Müller C,
Schrezenmeier H, Mytilineos J. HLA-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute
leukemia patients. Haematologica. 2017 Sep 7.
6. Hefter M, Lother J, Weiß E, Schmitt AL, Fliesser M, Einsele H, Loeffler J. Human primary myeloid dendritic cells interact with the
opportunistic fungal pathogen Aspergillus fumigatus via the C-type lectin receptor Dectin-1. Med Mycol. 2017 Jul.

7. Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S,Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, Maschmeyer G. Diagnosis and empiricaltreatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017 Nov Wurster S, Weis P, Page L, Helm J, Lazariotou M, Einsele H, Ullmann AJ. ntra- and inter-individual variability of Aspergillus fumigatus reactive T-cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment. Mycoses. 2017 Oct.
8. Wurster S, Thielen V, Weis P, Walther P, Elias J, Waaga-Gasser AM, Dragan M, Dandekar T, Einsele H, Löffler J, Ullmann AJ.
Mucorales spores induce a proinflammatory cytokine response in human mononuclear phagocytes and harbor no rodlet hydrophobins.
Virulence. 2017 Aug 7.
9. Ziegler S, Weiss E, Schmitt AL, Schlegel J, Burgert A, Terpitz U, Sauer M, Moretta L, Sivori S, Leonhardt I, Kurzai O, Einsele H, Loeffler
J. CD56 Is a Pathogen Recognition Receptor on Human Natural Killer Cells. Sci Rep. 2017 Jul 21.
10. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T,
Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C,
Richardson PG. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in
the PANORAMA 1 trial. Br J Haematol. 2017 Jun 27.
11. Went M, Sud A, Law PJ, Johnson DC, Weinhold N, Försti A, van Duin M, Mitchell JS, Chen B, Kuiper R, Stephens OW, Bertsch U,
Campo C, Einsele H, Gregory WM, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho
MI, Thomsen H, Walker BA, Broyl A, Davies FE, Langer C, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Hemminki K, Nilsson
B, Morgan GJ, Houlston RS. Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation
approach. Blood Cancer J. 2017 Jun 16.
12. Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM,
Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M,
Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo
A; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann
Oncol. 2017 May 24.
13. Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S,
Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM. CXCR4-directed endoradiotherapy induces high response rates in extramedullary
relapsed Multiple Myeloma. Theranostics. 2017 Apr 8;7(6):1589-1597.
14. Fuji S, Einsele H, Kapp M. Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic
options. Curr Opin Infect Dis. 2017 Aug;30(4):372-376.
15. Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema
MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with
ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017 May 9.
16. García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, Hudecek M. Panobinostat induces
CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood. 2017 Jun 22;129(25):3386-3388.
17. Lapa C, Schreder M, Lückerath K, Samnick S, Rudelius M, Buck AK, Kortüm KM, Einsele H, Rosenwald A, Knop S. [11 C]Methionine
emerges as a new biomarker for tracking active myeloma lesions. Br J Haematol. 2017 May 3. doi: 10.1111/ bjh.14696.
18. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H,
Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Apr 27.
19. Etc.